COVID-19 Vaccine Adjuvant Potentials of Nichi Glucan Dietary Supplement From Japan
ß - glucan produced by AFO-202 strain of black yeast Aureobasidium Pullulans (Nichi Glucan), having immune enhancement potentials through all major pathways, has been recommended worth clinical studies for validation as a vaccine adjuvant in COVID-19 (https://doi.org/10.1080/21645515.2021.1880210 ). Pathogens entering through nasal or oral route are tackled by mucosal immunity and antibodies in saliva and once inside the body by innate and adaptive immune systems and the trained immunity (TRIM). Nichi Glucan may have beneficial effects through all the above, describes the scientific publication journal associated with the International Society of Vaccines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005365/en/
Nichi Glucan as vaccine adjuvant: Adjuvants are agents that supplement vaccines by enhancing or stabilizing them. Nichi glucan with immunomodulating potential is considered more advantageous as it’s vaccine adjuvant efficacy against Avian influenza (H5N1, H5N2) have been reported (https://pubmed.ncbi.nlm.nih.gov/21532325/ ), has a safety track record of consumption as a food supplement in Japan since 1996 and beneficial effects in general health documented in human studies described below.
- Immune enhancement and balancing benefits in studies in cancer patients, young adults and elderly healthy volunteers (https://doi.org/10.3389/fimmu.2020.01548 )
- Coagulopathy related to COVID-19, could be tackled in populations at high-risk for blood clotting disorders; Thrombosis (https://doi.org/10.1186/s12959-020-00239-6 )
- Balancing of blood sugar and cholesterol potential may reduce mortality in SARS-CoV-2 patients; Journal of Diabetes & Metabolic Disorders (https://doi.org/10.1007/s40200-020-00664-4 ).
- Beta glucans in Trained immunity is reported to be more robust as they act on bone marrow which produces blood components and immune cells.
Earlier, associates of GN Corporation were granted a patent on Influenza Neutralizing Antibody to identify vulnerable population for vaccine administration, accomplished in collaboration with Dr. Yoshikazu Kurosawa, a monoclonal antibody researcher, recognized by Prof. Susumu Tonegawa in his Nobel prize for medicine – lecture in 1987 (https://www.nobelprize.org/uploads/2018/06/tonegawa-lecture.pdf ).
Human beings lack an ability to advantageously mutate their DNA or RNA unlike viruses; therefore, left with the only option of boosting their immune system for protection from evolving new pathogens and mutating viruses. Fungi having contributed significantly to human health yielding antimicrobial agents such as Penicillin and many anti-cancer agents, further research on this black yeast looks very promising said Dr. Gene Kurosawa, a co-author. Clinical studies on prebiotic potentials of Nichi Glucan to solve gut dysbiosis by balancing gut microbiota are underway.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
COMPUTEX-TAIPEI13.4.2021 08:54:07 CEST | Press release
Acer, AMD, Arm, Intel, Micron, NXP, Qualcomm and Supermicro Confirm Participation in COMPUTEX 2021 Hybrid
ESHOPWORLD13.4.2021 08:03:35 CEST | Press release
eShopWorld Appoints Martim Avillez Oliveira as Chief Commercial Officer - EMEA and APAC
EPIENDO-PHARMACEUTICALS13.4.2021 08:02:35 CEST | Press release
EpiEndo Pharmaceuticals Announces Launch of First-in-Human Clinical Trial of a Non-Antibiotic Macrolide for the Treatment of Chronic Inflammatory Airway Diseases
BIOCORP13.4.2021 08:02:14 CEST | Press release
BIOCORP and ROCHE DIABETES CARE FRANCE Launch Mallya, an Innovative Medical Device to Better the Daily Life of Patients With Diabetes
CA-KYOTO-SEMICONDUCTOR13.4.2021 03:02:11 CEST | Press release
Kyoto Semiconductor Signs Supply and Reseller Agreement With CEL
TX-MAVENIR12.4.2021 19:03:06 CEST | Press release
Mavenir Launches 5G Hyperconverged Edge AI Solution for Enterprise & Telco Market Based on NVIDIA Platforms
CA-QUANTA-CLOUD12.4.2021 19:03:06 CEST | Press release
QCT Unveils Optimized Accelerated Server to Boost High-Performance Workloads
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom